30. April 2012 12:10
An increase in sales at the ‘new Genzyme’ helped Sanofi’s business EPS grow by 7.2% as revenue topped €8.5bn in the first three months of 2012.
Sales of growth platforms, which include Genzyme, were €5.38bn and accounted for 63.2% of total sales, up from 59.2% in Q1 2011, despite global generic competition on Plavix and Aprovel.
Jérôme Contamine, Executive Vice President, Chief Financial Officer discusses the Q1 results.
Jérôme Contamine discusses Sanofi's Q1 figures